Abbott’s Freestyle Libre 3 system has recieved a Conformité Européenne (CE) mark on their automatic real-time glucose reading device that sends direct alarms to smartphones for people with diabetes.
The Freestyle Libre 3 system is the smallest and thinnest wearable glucose sensor that can monitor glucose levels discreetly and conveniently at any time. The device sends readings to a smartphone every minute offering unsurpassed 14-day accuracy.
The current system is based on the last FreeStyle Libre 2 sensor but with a new sensor design and at an affordable price.
“Abbott won’t stop innovating when there’s room to raise the bar. We’ve done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy,” Jared Watkin, senior vice president of Diabetes Care for Abbott, said in a statement. “People living with diabetes are at the center of our design process, and we made our next-generation technology even more discreet for a better user experience to make managing diabetes as easy and seamless as possible.”
The system is worn on the back of the upper arm as a one-piece applicator, eliminating the need for a painful fingerstick. The wear time is 14 days, which is the longest-lasting, self-applied CGM sensor available.
“Since we launched the first disposable glucose sensor in 2014, we’ve always believed all people with diabetes should have access to high-quality, accurate and affordable diabetes technologies,” said Watkin. “That’s why Abbott disrupted the traditional notion that CGMs have to sacrifice quality or accuracy for affordability, and we built our FreeStyle Libre family of products to deliver unparalleled results at a lower cost than any other CGM available.”
The mobile application is designed to enable users to capture and view their real-time glucose levels, glucose history and trend arrows showing how the customer’s glucose levels are changing with just a glance at their app.
The design of the FreeStyle Libre 3 system is to be more sustainable for the environment with a smaller and more discreet sensor. The device has a reduction of 41 percent in plastic and 43 percent in carton paper. This design aligns with the company’s commitment to becoming more sustainable.
Abbott is launching the FreeStyle Libre 3 system in Europe in the coming months. It has been proven to improve glucose control and increase time in the target glucose range, decrease time in hyperglycemia and lower HbA1c. These are contributing to better health outcomes for patients with diabetes.
This in turn reduces diabetes-related hospital admissions and work absentee rates to improve their quality of life.
Abbott’s FreeStyle Libre portfolio has changed the lives of more than two million people across 50 countries. They provide breakthrough technology that is accessible and affordable. Abbott secured partial or full reimbursement for FreeStyle Libre System in 37 countries, including the US, Canada and the UK.